The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
SIROLIMUS: A POTENT NEW IMMUNOSUPPRESSANT FOR LIVER TRANSPLANTATION
Abstract
BACKGROUND: Sirolimus (rapamycin) is a new immunosuppressant that appears to be synergistic with cyclosporine in kidney transplantation, but with a different side-effect profile. This pilot study evaluated sirolimus in liver transplantation. METHODS: Patients undergoing orthotopic liver transplantation for primary tumors (8), and later for nonmalignant disease (7), received one of three sirolimus-based immunosuppressive regimens. Protocol A comprised sirolimus, microemulsion cyclosporine (target whole blood concentration: 100 ng/ml), and prednisolone; protocol B omitted prednisolone; and protocol C was sirolimus alone. By 3 months after transplantation, all patients were receiving sirolimus as monotherapy. RESULTS: Fifteen patients were treated with a follow-up of 117-806 days. Rejection was more common on monotherapy than double therapy, and absent on triple therapy. The drug was generally well tolerated, with only three patients discontinuing sirolimus: one for hyperlipidemia, one for pneumocystis pneumonia, and one for inability to tolerate the taste of the drug. Two patients discontinued cyclosporine early, both as a result of neurological complications; they continued on sirolimus monotherapy. Five patients died; one suffered a cardiac arrest, and four died from sepsis in association with graft-versus-host disease, recurrent tumor, a paralyzed right hemidiaphragm, and primary nonfunction. CONCLUSIONS: Sirolimus combined with cyclosporine provided potent immunosuppression of liver allografts, and sirolimus monotherapy was adequate and well tolerated as maintenance therapy. Side effects of sirolimus over the short period of follow-up were uncommon and reversible with dose reduction or cessation of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Cited by
Taylor, A. L., Watson, C. J. E., & Bradley, J. A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.012 · Cited by 445
Self-citationSirolimus-tacrolimus combination immunosuppression
McAlister, V. C., Gao, Z., Peltekian, K., Domingues, J., Mahalati, K., & MacDonald, A. S. (2000) · The Lancet · doi:10.1016/s0140-6736(99)03882-9 · Cited by 323
Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m100392-jlr200 · Cited by 295
Kneteman, N. M., Oberholzer, J., Al Saghier, M., Meeberg, G. A., Blitz, M., Ma, M. M., Wong, W. W. S., Gutfreund, K., Mason, A. L., Jewell, L. D., et al. (2004) · Liver Transplantation · doi:10.1002/lt.20237 · Cited by 256
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Metadata
- Authors
- Watson, C. J. E., Friend, P. J., Jamieson, N. V., Frick, T. W., Alexander, G., Gimson, A. E., & Calne, R.
- Venue
- Transplantation
- Published
- 1999-02
- Volume
- 67
- Issue
- 4
- Pages
- 505-509
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2110872657
- Cited by
- 204
- References
- 1
- FWCI
- 17.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SIROLIMUS: A POTENT NEW IMMUNOSUPPRESSANT FOR LIVER TRANSPLANTATION. https://app.cochat.ai/papers/10.1097/00007890-199902270-00002
- The paper
- Watson, C. J. E., Friend, P. J., Jamieson, N. V., Frick, T. W., Alexander, G., Gimson, A. E., & Calne, R. (1999). SIROLIMUS: A POTENT NEW IMMUNOSUPPRESSANT FOR LIVER TRANSPLANTATION. Transplantation. https://doi.org/10.1097/00007890-199902270-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.